Intervene With Jakafi
For treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea,
intervene with Jakafi to achieve durable count control.
For treatment of intermediate- or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults,
Jakafi at diagnosis.
For treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older,
intervene with Jakafi.
Experience with Jakafi since FDA approval1*
MORE THAN 30,000 PATIENTS TREATED
*Estimated total patients treated with commercially available Jakafi in the US since 2011.1
- Data on file. Incyte Corporation. Wilmington, DE.